



**Frank Seibold**

**Contact**

Frank Seibold

## Publications (10)

Biedermann L, Franke A, Seibold F, Quattropani C, Straumann A, Schoepfer A, Hruz P. Eosinophile Ösophagitis. *Swiss Medical Forum* 2022; 22(49-50):800-804.

Sulz M, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment Algorithms for Crohn's Disease. *Digestion* 2020; 101 Suppl 1:43-57.

Greuter T, Vavricka S, Biedermann L, Pilz J, Borovicka J, Seibold F, Sauter B, Rogler G. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. *Dig Dis* 2017

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Manser C, Borovicka J, Seibold F, Vavricka S, Lakatos P, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. *United European Gastroenterol J* 2016; 4:281-7.

Phillips A, van den Berg L, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson D, Westra H, Xavier R, Zhao Z, Ponsioen C, Andersen V, Torkvist L, Targan S, Steinhart A, Prescott N, Proctor D, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms L, Seielstad M, Gazouli M, Anagnou N, Satsangi J, Cho J, Schreiber S, Daly M, Barrett J, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr R, Vermeire S, Weersma R, Chamailard M, Brant S, Karlsen T, Kupcinskas L, Sventoraityte J, Mansfield J, Kugathasan S, Silverberg M, Halfvarson J, Rotter J, Mathew C, Griffiths A, Geary R, Ahmad T, Rioux J, Panés J, Anderson C, Baldassano R, Barclay M, Bayless T, Brand S, Büning C, Colombel J, Denson L, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann R, Baidoo L, Bumpstead S, Boucher G, Lees C, Franke A, D'Amato M, Taylor K, Lee J, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Floyd J, Florin T, Libioulle C, Louis E, McGovern D, Milla M, Montgomery G, Morley K, Mowat C, Ng A, Newman W, Ophoff R, Papi L, Palmieri O, Levine A, Lemann M, Franchimont D, Franke L, Georges M, Glas J, Glazer N, Guthery S, Haritunians T, Hayward N, Hugot J, Jobin G, Laukens D, Lawrance I, Peyrin-Biroulet L. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011; 43:246-52.

Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Banský G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. *Inflamm Bowel Dis* 2010

Glas J, Mowat C, Newman W, Panés J, Phillips A, Proctor D, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Louis E, Libioulle C, Van Gossum A, Guthery S, Halfvarson J, Verspaget H, Hugot J, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Seibold F, Steinhart A, Mansfield J, Vermeire S, Duerr R, Silverberg M, Satsangi J, Schreiber S, Cho J, Annese V, Hakonarson H, Daly M, Griffiths A, Kugathasan S, Stokkers P, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan S, Brant S, Rioux J, D'Amato M, Weersma R, Parkes M, Franke A, Ellinghaus D, Festen E, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew C, Montgomery G, Prescott N, Bumpstead S, Bis J, McGovern D, Barrett J, Wang K, Radford-Smith G, Ahmad T, Lees C, Balschun T, Lee J, Roberts R, Anderson C, Raychaudhuri S, Rotter J, Colombel J, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Cohen A, Büning C, Schumm P, Sharma Y, Simms L, Taylor K, Whiteman D, Wijmenga C, Baldassano R, Barclay M, Bayless T, Brand S, Geary R. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010; 42:1118-25.

Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. *Inflammatory bowel diseases* 2009

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)